Serum 14-3-3η as predictor of clinical remission and progression of structural damage in early rheumatoid arthritis following a treat-to-target strategy in a randomized controlled trial
Authors' conclusion
Serum 14-3-3η was a borderline significant predictor of radiographic progression, particularly in ACPA-negative patients, but not of predicting achievement of clinical remission.
Study context
- Population
- Patients with early rheumatoid arthritis (RA) in the OPERA trial, treat-to-target strategy
- Participants
- 180 patients
- Comparison
- Baseline serum 14-3-3η as predictor of Disease Activity Score-C-reactive protein (DAS28-CRP) remission and radiographic progression
- Primary endpoint
- Prediction of DAS28-CRP remission (<2.6) at 6 months and radiographic progression (TSS change >1.8 units) at 12 months by baseline serum 14-3-3η
Methodological detailsdouble-blinded, randomized, multivariate logistic regression
- Double-blinded
- Randomized
- Multivariate logistic regression
Primary result
As reported in the abstract
Radiographic progression, baseline 14-3-3η as independent predictor · 12 months
OR per unit baseline 14-3-3η (borderline significant), 95% CI 1.00-1.03, p = 0.05
1.02
Further findings
Radiographic progression in ACPA-negative patients, by baseline 14-3-3η (subgroup) · 12 months
χ2 4.823 · P = 0.028
Original publication
Serum 14-3-3η as predictor of clinical remission and progression of structural damage in early rheumatoid arthritis following a treat-to-target strategy in a randomized controlled trial. Scand J Rheumatol. Published 14 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →